Fallopian Tube Cancer Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

New Drug Treats Female Reproductive Cancers
Am J Nurs. 2023 Apr 1;123(4):25. doi: 10.1097/01.NAJ.0000925492.07716.f4.ABSTRACTMirvetuximab soravtansine-gynx (Elahere) has been granted accelerated approval to treat adult patients with folate receptor α-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.The drug's labeling includes a boxed warning for ocular toxicity. Other warnings include a risk of pneumonitis, peripheral neuropathy, and embryo-fetal toxicity.PMID:36951341 | DOI:10.1097/01.NAJ.0000925492.07716.f4 (Source: The American Journal of Nursing)
Source: The American Journal of Nursing - March 23, 2023 Category: Nursing Authors: Diane S Aschenbrenner Source Type: research

Pregnancy-associated gynecological cancer in New South Wales, Australia 1994-2013: A population-based historical cohort study
CONCLUSIONS: The incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women.PMID:36915236 | DOI:10.1111/aogs.14530 (Source: Cancer Control)
Source: Cancer Control - March 14, 2023 Category: Cancer & Oncology Authors: Penelope Fotheringham Nadom Safi Zhouyang Li Antoinette Anazodo Marc Remond Andrew Hayen David Currow David Roder Nada Hamad Michael Nicholl Adrienne Gordon Jane Frawley Elizabeth A Sullivan Source Type: research

Pregnancy ‐associated gynecological cancer in New South Wales, Australia 1994–2013: A population‐based historical cohort study
ConclusionsThe incidence of PAGC has not increased over time perhaps reflecting, in part, the effectiveness of cervical screening and early impacts of human papillomavirus vaccination programs in Australia. The higher rate of preterm birth among the gestational PAGC group is associated with adverse outcomes in babies born to these women. (Source: Acta Obstetricia et Gynecologica Scandinavica)
Source: Acta Obstetricia et Gynecologica Scandinavica - March 14, 2023 Category: OBGYN Authors: Penelope Fotheringham, Nadom Safi, Zhouyang Li, Antoinette Anazodo, Marc Remond, Andrew Hayen, David Currow, David Roder, Nada Hamad, Michael Nicholl, Adrienne Gordon, Jane Frawley, Elizabeth A. Sullivan Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study
In conclusion, patients with primary platinum sensitive disease who received fewer prior lines of chemotherapy were able to receive more cycles of bevacizumab, which was associated with improved overall survival. Survival worsened when bevacizumab was initiated later in the ordinal sequence of therapies.PMID:36874058 | PMC:PMC9980410 | DOI:10.22514/ejgo.2023.002 (Source: European Journal of Gynaecological Oncology)
Source: European Journal of Gynaecological Oncology - March 6, 2023 Category: OBGYN Authors: Talayeh S Ghezelayagh Emily S Wu Emma L Barber Minh D Dao Emese Zsiros Renata R Urban Heidi J Gray Barbara A Goff Chirag A Shah Nikki L Neubauer James Y Dai Janos L Tanyi John B Liao Source Type: research